Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Nanette Santoro to Hot Flashes

This is a "connection" page, showing publications Nanette Santoro has written about Hot Flashes.

 
Connection Strength
  
 
 
10.696
  
  1. Zalles L, Santoro N. Nonhormonal treatments for vasomotor symptoms. Curr Opin Obstet Gynecol. 2025 Oct 01; 37(5):326-331.
    View in: PubMed
    Score: 0.863
  2. Santoro N. Novel nonhormonal treatments for vasomotor symptoms of menopause. Curr Opin Obstet Gynecol. 2025 Aug 01; 37(4):193-197.
    View in: PubMed
    Score: 0.850
  3. Santoro N, Neal-Perry G, Stute P, Blogg M, Mancuso S, Morga A, Ottery FD, Siddiqui E. Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy. Curr Med Res Opin. 2025 Feb; 41(2):375-384.
    View in: PubMed
    Score: 0.841
  4. Santoro N. Neurokinin receptor antagonists as potential nonhormone treatments for vasomotor symptoms. Menopause. 2024 Oct 01; 31(10):923-925.
    View in: PubMed
    Score: 0.812
  5. Santoro N, Nappi RE, Neal-Perry G, English M, King DD, Yamaguchi Y, Ottery FD. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Menopause. 2024 Apr 01; 31(4):247-257.
    View in: PubMed
    Score: 0.789
  6. Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C, Lee M, Santoro N. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. J Clin Endocrinol Metab. 2023 07 14; 108(8):1981-1997.
    View in: PubMed
    Score: 0.751
  7. Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Menopause. 2017 03; 24(3):238-246.
    View in: PubMed
    Score: 0.483
  8. Santoro N. Feed a hot flash, starve a hot flash? Menopause. 2017 01; 24(1):1-2.
    View in: PubMed
    Score: 0.478
  9. Umland EM, Karel L, Santoro N. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause. Pharmacotherapy. 2016 05; 36(5):548-61.
    View in: PubMed
    Score: 0.457
  10. Santoro N. Perimenopause: From Research to Practice. J Womens Health (Larchmt). 2016 Apr; 25(4):332-9.
    View in: PubMed
    Score: 0.444
  11. Al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil Steril. 2014 Apr; 101(4):905-15.
    View in: PubMed
    Score: 0.393
  12. Santoro N. Symptoms of menopause: hot flushes. Clin Obstet Gynecol. 2008 Sep; 51(3):539-48.
    View in: PubMed
    Score: 0.268
  13. Pal L, Norian J, Zeitlian G, Bevilacqua K, Freeman R, Santoro N. Vasomotor symptoms in infertile premenopausal women: a hitherto unappreciated risk for low bone mineral density. Fertil Steril. 2008 Nov; 90(5):1626-34.
    View in: PubMed
    Score: 0.258
  14. Winkles JF, Santoro N, Sammel MD, El Khoudary SR, Colvin A, Crawford S. Measuring associations between hormonal entropy, the prevalence of vasomotor symptoms, and menstrual dynamics. Am J Physiol Endocrinol Metab. 2025 Nov 01; 329(5):E603-E615.
    View in: PubMed
    Score: 0.219
  15. Santoro N. Understanding the menopause journey. Climacteric. 2025 Aug; 28(4):384-388.
    View in: PubMed
    Score: 0.209
  16. Shapiro C M M, Cano A, Nappi RE, Santoro N, English ML, Mancuso S, Morga A, Siddiqui E, Valluri U, Ottery FD. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause. Maturitas. 2024 Aug; 186:107999.
    View in: PubMed
    Score: 0.199
  17. Cano A, Nappi RE, Santoro N, Stute P, Blogg M, English ML, Morga A, Scrine L, Siddiqui E, Ottery FD. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG. 2024 Aug; 131(9):1296-1305.
    View in: PubMed
    Score: 0.195
  18. Kracht CL, St Romain J, Hardee JC, Santoro N, Redman LM, Marlatt KL. "Weight loss is my goal and being healthy is my goal? I can get over the hot flashes": a qualitative exploration of menopausal transition experiences and preferences for weight management among White women. Menopause. 2023 10 01; 30(10):1022-1032.
    View in: PubMed
    Score: 0.190
  19. Zapantis G, Santoro N. The menopausal transition: characteristics and management. Best Pract Res Clin Endocrinol Metab. 2003 Mar; 17(1):33-52.
    View in: PubMed
    Score: 0.183
  20. Santoro N, Roeca C, Peters BA, Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021 01 01; 106(1):1-15.
    View in: PubMed
    Score: 0.158
  21. Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020 12; 27(12):1350-1356.
    View in: PubMed
    Score: 0.157
  22. Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, Skillern L, Ramael S. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020 04; 27(4):382-392.
    View in: PubMed
    Score: 0.150
  23. Lobo RA, Kaunitz AM, Santoro N, Bernick B, Graham S, Mirkin S. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. Climacteric. 2019 12; 22(6):610-616.
    View in: PubMed
    Score: 0.143
  24. Allshouse A, Pavlovic J, Santoro N. Menstrual Cycle Hormone Changes Associated with Reproductive Aging and How They May Relate to Symptoms. Obstet Gynecol Clin North Am. 2018 Dec; 45(4):613-628.
    View in: PubMed
    Score: 0.135
  25. Delamater L, Santoro N. Management of the Perimenopause. Clin Obstet Gynecol. 2018 09; 61(3):419-432.
    View in: PubMed
    Score: 0.134
  26. Thurston RC, Chang Y, Barinas-Mitchell E, Jennings JR, Landsittel DP, Santoro N, von Känel R, Matthews KA. Menopausal Hot Flashes and Carotid Intima Media Thickness Among Midlife Women. Stroke. 2016 12; 47(12):2910-2915.
    View in: PubMed
    Score: 0.118
  27. Santoro N, Teal S, Gavito C, Cano S, Chosich J, Sheeder J. Use of a levonorgestrel-containing intrauterine system with supplemental estrogen improves symptoms in perimenopausal women: a pilot study. Menopause. 2015 Dec; 22(12):1301-7.
    View in: PubMed
    Score: 0.111
  28. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015 Sep; 44(3):497-515.
    View in: PubMed
    Score: 0.109
  29. Thurston RC, Santoro N, Matthews KA. Are vasomotor symptoms associated with sleep characteristics among symptomatic midlife women? Comparisons of self-report and objective measures. Menopause. 2012 Jul; 19(7):742-8.
    View in: PubMed
    Score: 0.087
  30. Thurston RC, Santoro N, Matthews KA. Adiposity and hot flashes in midlife women: a modifying role of age. J Clin Endocrinol Metab. 2011 Oct; 96(10):E1588-95.
    View in: PubMed
    Score: 0.082
  31. Green R, Polotsky AJ, Wildman RP, McGinn AP, Lin J, Derby C, Johnston J, Ram KT, Crandall CJ, Thurston R, Gold E, Weiss G, Santoro N. Menopausal symptoms within a Hispanic cohort: SWAN, the Study of Women's Health Across the Nation. Climacteric. 2010 Aug; 13(4):376-84.
    View in: PubMed
    Score: 0.077
  32. Green R, Santoro N. Menopausal symptoms and ethnicity: the Study of Women's Health Across the Nation. Womens Health (Lond). 2009 Mar; 5(2):127-33.
    View in: PubMed
    Score: 0.069
  33. Crawford SL, Avis NE, Gold E, Johnston J, Kelsey J, Santoro N, Sowers M, Sternfeld B. Sensitivity and specificity of recalled vasomotor symptoms in a multiethnic cohort. Am J Epidemiol. 2008 Dec 15; 168(12):1452-9.
    View in: PubMed
    Score: 0.068
  34. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol. 2008 Oct; 19(10):1669-80.
    View in: PubMed
    Score: 0.066
  35. Cintron D, Lahr BD, Bailey KR, Santoro N, Lloyd R, Manson JE, Neal-Perry G, Pal L, Taylor HS, Wharton W, Naftolin F, Harman SM, Miller VM. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause. 2018 02; 25(2):145-153.
    View in: PubMed
    Score: 0.032
  36. Thurston RC, Chang Y, Barinas-Mitchell E, von Känel R, Jennings JR, Santoro N, Landsittel DP, Matthews KA. Child Abuse and Neglect and Subclinical Cardiovascular Disease Among Midlife Women. Psychosom Med. 2017 May; 79(4):441-449.
    View in: PubMed
    Score: 0.031
  37. Thurston RC, Chang Y, von Känel R, Barinas-Mitchell E, Jennings JR, Hall MH, Santoro N, Buysse DJ, Matthews KA. Sleep Characteristics and Carotid Atherosclerosis Among Midlife Women. Sleep. 2017 Feb 01; 40(2).
    View in: PubMed
    Score: 0.030
  38. Davis SR, Lambrinoudaki I, Lumsden M, Mishra GD, Pal L, Rees M, Santoro N, Simoncini T. Menopause. Nat Rev Dis Primers. 2015 04 23; 1:15004.
    View in: PubMed
    Score: 0.027
  39. Skurnick JH, Weiss G, Goldsmith LT, Santoro N, Crawford S. Longitudinal changes in hypothalamic and ovarian function in perimenopausal women with anovulatory cycles: relationship with vasomotor symptoms. Fertil Steril. 2009 Apr; 91(4):1127-34.
    View in: PubMed
    Score: 0.016
  40. Johnson TM, Cohen HW, Howard AA, Santoro N, Floris-Moore M, Arnsten JH, Hartel DM, Schoenbaum EE. Attribution of menopause symptoms in human immunodeficiency virus-infected or at-risk drug-using women. Menopause. 2008 May-Jun; 15(3):551-7.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)